David A Kircher
Overview
Explore the profile of David A Kircher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almazan J, Turapov T, Kircher D, Stanley K, Culver K, Medellin A, et al.
Cell Rep Med
. 2025 Feb;
6(2):101943.
PMID: 39922199
This study addresses the urgent need for effective therapies for patients with brain metastases from cutaneous melanoma, a major cause of treatment failure despite recent therapeutic advances. Utilizing mouse models...
2.
Guerrieri R, Fischer G, Kircher D, Joon A, Cortez J, Grossman A, et al.
bioRxiv
. 2025 Feb;
PMID: 39896644
Structured Abstract: Melanoma mortality is driven by the formation and growth of distant metastases. However, the process and pathogenesis of melanoma metastasis remain poorly understood. Here, we interrogate the role...
3.
Parkman G, Turapov T, Kircher D, Burnett W, Stehn C, OToole K, et al.
Mol Cancer Ther
. 2023 Nov;
23(3):301-315.
PMID: 37931033
Aberrant activation of the PI3K-AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1-3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts...
4.
Parkman G, Foth M, Kircher D, Holmen S, McMahon M
Exp Dermatol
. 2021 Oct;
31(1):43-56.
PMID: 34717019
Phosphatidylinositol-3'-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3' hydroxyl (OH) of the inositol ring of phosphatidylinositides (PI). Through their downstream effectors, PI3K generated lipids (PI3K-lipids hereafter)...
5.
Parkman G, Kircher D, Stehn C, McMahon M, Holmen S
Pigment Cell Melanoma Res
. 2020 Oct;
34(3):655-658.
PMID: 33098202
No abstract available.
6.
Kircher D, Trombetti K, Silvis M, Parkman G, Fischer G, Angel S, et al.
Mol Cancer Res
. 2019 May;
17(9):1787-1800.
PMID: 31138602
Alterations in the PI3K/AKT pathway occur in up to 70% of melanomas and are associated with disease progression. The three AKT paralogs are highly conserved but data suggest they have...
7.
Yoo J, Brady S, Acosta-Alvarez L, Rogers A, Peng J, Sorensen L, et al.
Cancer Res
. 2019 May;
79(11):2892-2908.
PMID: 31048499
Melanoma has an unusual capacity to spread in early-stage disease, prompting aggressive clinical intervention in very thin primary tumors. Despite these proactive efforts, patients with low-risk, low-stage disease can still...
8.
Fischer G, Jalali A, Kircher D, Lee W, McQuade J, Haydu L, et al.
Cancer Discov
. 2019 Feb;
9(5):628-645.
PMID: 30787016
There is a critical need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial...
9.
Robinson J, Rebecca V, Kircher D, Silvis M, Smalley I, Gibney G, et al.
Melanoma Res
. 2017 Oct;
27(6):545-557.
PMID: 29076949
Targeted therapies have revolutionized cancer care, but the development of resistance remains a challenge in the clinic. To identify rational targets for combination strategies, we used an established melanoma mouse...
10.
Kircher D, Silvis M, Cho J, Holmen S
Int J Mol Sci
. 2016 Sep;
17(9).
PMID: 27598148
The development of brain metastases in patients with advanced stage melanoma is common, but the molecular mechanisms responsible for their development are poorly understood. Melanoma brain metastases cause significant morbidity...